BMJ  2007;334:177 (27 January), doi:10.1136/bmj.39104.352616.DB

News

FDA proposes higher fees for drug approvals to cover postmarketing surveillance

Janice Hopkins Tanne

1 New York

The first 150 words of the full text of this article appear below.

The US Food and Drug Administration has agreed with pharmaceutical manufacturers on an almost 30% increase in the "user fees" that drug makers pay to the FDA to expedite approval of new drugs. The FDA has also consulted patient advocates, consumer groups, health professionals, and academic researchers about the new rules.

User fees are annual fees paid by pharmaceutical manufacturers. The FDA wants them to increase by $87.4m to $392.8m (£199.0m; {euro}303.7m). The FDA now gets more than half of its funding from user fees.

The agency will hold a public meeting in Washington, DC, on 16 February to hear comments and will then ask Congress to approve the new rules.

The FDA says the largest portion of the new fees—$29.3m—will help it increase postmarketing surveillance of newly approved drugs beyond the current three years. The agency has been criticised for not detecting the cardiovascular risks of COX 2 (cyclo-oxygenase-2) . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Access jobs at BMJ Careers
Whats new online at Student BMJ